DEREK ANDRZEJEWSKI: Open Payments
NPI 1437785268 · SEATTLE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,686 in 158 payments from 25 companies in 2025. Trend: 2023 $2,907 · 2024 $3,112 · 2025 $3,686
Food & beverage: $3,686
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 15 | $483 |
| AstraZeneca Pharmaceuticals LP | 17 | $403 |
| GlaxoSmithKline, LLC. | 25 | $365 |
| PFIZER INC. | 14 | $305 |
| Regeneron Healthcare Solutions, Inc. | 14 | $304 |
| Novartis Pharmaceuticals Corporation | 12 | $260 |
| Amgen Inc. | 14 | $247 |
| Ionis Pharmaceuticals, Inc. | 7 | $221 |
| Galderma Laboratories, L.P. | 7 | $202 |
| CSL Behring | 5 | $137 |
Products named: DUPIXENT, TEZSPIRE, NUCALA, NEMLUVIO, DAWNZERA, AYVAKIT, FASENRA, CIBINQO.
Industry payments across WA — which companies pay providers there.
